OBJECTIVE
The purpose of this study was to investigate adverse reaction reports of pain and/or cyanosis attributed to alpha 1-proteinase inhibitor (A1PI), a plasma alpha-globulin protein used to treat A1PI deficiency.
METHODS
The Food and Drug Administration's (FDA) Spontaneous Reporting System for